方盛制药（603998）8月14日主力资金净流出2060.26万元

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Fangsheng Pharmaceutical, indicating a decline in revenue but an increase in net profit [1] - As of August 14, 2025, Fangsheng Pharmaceutical's stock closed at 11.05 yuan, down 1.78%, with a turnover rate of 4.24% and a trading volume of 186,300 hands, amounting to 209 million yuan [1] - The company's latest quarterly report shows total operating revenue of 418 million yuan, a year-on-year decrease of 4.62%, while net profit attributable to shareholders reached 88.26 million yuan, a year-on-year increase of 25.74% [1] Group 2 - The company has a current liquidity ratio of 0.829, a quick ratio of 0.511, and a debt-to-asset ratio of 44.14% [1] - Fangsheng Pharmaceutical has made investments in 42 enterprises and participated in 4,797 bidding projects, indicating active engagement in the market [2] - The company holds 115 trademark registrations and 62 patents, along with 170 administrative licenses, showcasing its intellectual property portfolio [2]